قرار
إداري رقم (90)
لسنة 2019
باعتماد
أثمان
خدمات
التحاليل
المخبرية لدى
هيئة الصحة في
دبي
___________________
المدير
العام
بعد
الاطلاع على
القانون رقم (14)
لسنة 2009 بشأن تسعير
الخدمات
الحكومية في
إمارة دبي
وتعديلاته،
وعلى
القانون رقم (32)
لسنة 2015 بشأن
الجريدة
الرسمية
لحكومة دبي،
وعلى
القانون
رقم (1) لسنة 2016
بشأن النظام
المالي لحكومة
دبي،
وعلى
القانون رقم (6)
لسنة 2018 بشأن
هيئة الصحة في
دبي، ويُشار
إليها فيما
بعد بـِ
"الهيئة"،
وعلى
المرسوم رقم (9)
لسنة 2012
باعتماد آلية
تسعير خدمات
هيئة الصحة في
دبي،
وعلى
المرسوم رقم (17)
لسنة 2018 بشأن
إنشاء
المؤسسات
التابعة
لهيئة الصحة
في دبي وتحديد
اختصاصاتها،
وعلى
المرسوم رقم (18)
لسنة 2018 بتعيين
مُدير عام
هيئة الصحة في
دبي،
وعلى
قرار المجلس
التنفيذي رقم
(18) لسنة 2018
باعتماد
الهيكل التنظيمي
لهيئة الصحة
في دبي،
وعلى
القرار
الإداري رقم (148)
لسنة 2014 بشأن
رسوم الخدمات
الصحية،
وعلى
القرار
الإداري رقم (210)
لسنة 2018 بشأن
تسعير التحاليل
المخبرية في
مختبرات
الهيئة
وبناءً
على موافقة
دائرة المالية
لحكومة دبي
بموجب كتابها
المؤرخ في 6/11/2018،
على تطبيق
الأسعار
الجديدة
لخدمات التحاليل
المخبرية لدى
هيئة الصحة في
دبي،
قررنا
ما يلي:
اعتماد
الأثمان
المادة
(1)
تُعتمد
بموجب هذا
القرار،
أثمان خدمات
التحاليل
المخبرية
التي يتم
إجراؤها في
المختبرات العائدة
للهيئة،
وفقاً لما هو
مبيّن في الجدول
المُلحق بهذا
القرار.
التكليف
بالتنفيذ
المادة (2)
على
كافة الوحدات
التنظيمية في
الهيئة، اتخاذ
الإجراءات
اللازمة لوضع
هذا القرار
موضع التنفيذ،
كل في مجال
اختصاصه.
الإلغاء
المادة (3)
يُلغى
القرار
الإداري رقم (210)
لسنة 2018 بشأن
تسعير
التحاليل
المخبرية في
مختبرات
الهيئة
المشار إليه
في الأسانيد،
كما يُلغى أي
حكم أو قرار
يتعارض مع
أحكام هذا القرار.
السريان
والنشر
المادة (4)
يُعمل
بهذا القرار
من تاريخ 25/12/2018م،
ويُنشر في
الجريدة
الرسمية.
حميد
القطامي
المدير
العام
صدر في
دبي بتاريخ 4
يوليو 2019م
المـــــــــــــــــــــــوافق
1 ذو القعدة 1440هـ
Schedule of Dubai Health
Authority Laboratory Test Prices
|
Sr. |
Billing
Code / Service Code |
Service
Description |
Proposed
Charge |
|
1 |
81378 |
HLA
Class I and II typing, high resolution (ie, alleles or allele groups), HLA-A,
-B, -C, and -DRB1 |
3000 |
|
2 |
81379 |
HLA
Class I typing, high resolution (ie, alleles or allele groups); complete (ie,
HLA-A, -B, and -C) |
2000 |
|
3 |
81382 |
HLA
Class II typing, high resolution (ie, alleles or allele groups); 1 locus (eg,
HLA-DRB1, -DRB3, -DRB4, -DRB5, -DQB1, -DQA1, -DPB1, or -DPA1), each |
2000 |
|
4 |
81251 |
GBA
(glucosidase, beta, acid) (eg, Gaucher disease) gene analysis, common
variants (eg, N370S, 84GG, L444P, IVS2+1G>A) |
500 |
|
5 |
81375 |
HLA
Class II typing, low resolution (eg, antigen equivalents); HLA-DRB1/3/4/5 and
-DQB1 |
1000 |
|
6 |
81374 |
HLA
Class I typing, low resolution (eg, antigen equivalents); 1 antigen equivalent
(eg, B*27), each |
350 |
|
7 |
81228 |
Cytogenomic
constitutional (genome-wide) microarray analysis; interrogation of genomic
regions for copy number variants (eg, Bacterial Artificial Chromosome [BAC]
or oligo-based comparative genomic hybridization [CGH] microarray analysis) |
4800 |
|
8 |
89240 |
Unlisted
miscellaneous pathology test |
310 |
|
9 |
81331 |
SNRPN/UBE3A
(small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase
E3A) (eg, Prader-Willi syndrome and/or Angelman syndrome), methylation
analysis |
440 |
|
10 |
2003074 |
SIALIDOSIS |
1350 |
|
11 |
2006046 |
BACTERIAL
ANTIGEN (CSF) |
0 |
|
12 |
2001446 |
Combine
Pitutary Adrenal Tests,Female |
0 |
|
13 |
2001447 |
Combine
Pitutary Adrenal Tests,Female |
0 |
|
14 |
2001448 |
Combine
Pitutary Adrenal Tests,Female |
0 |
|
15 |
2001443 |
Combine
Pitutary Adrenal Tests,Female |
0 |
|
16 |
2001450 |
Combine
Pitutary Adrenal Tests,Male |
0 |
|
17 |
2001453 |
Combine
Pitutary Adrenal Tests,Male |
0 |
|
18 |
2001454 |
Combine
Pitutary Adrenal Tests,Male |
0 |
|
19 |
2001455 |
Combine
Pitutary Adrenal Tests,Male |
0 |
|
20 |
3010140 |
CBU
MOLECULAR HLA TYPING |
2000 |
|
21 |
3010130 |
REGISTRATION
(CBU) |
1000 |
|
22 |
3010110 |
UNRELATED
CORD BLOOD DONATION |
0 |
|
23 |
3010135 |
PROCESSING
& CRYOPRESERV OF CBU |
8000 |
|
24 |
2004457 |
FOOD
INTOLERANCE TEST |
3000
gross = 2400 NET |
|
25 |
81270-1 |
JAK2
(Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe
(V617F) variant |
800 |
|
26 |
81270-2 |
JAK2
(Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe
(V617F) variant |
1289 |
|
27 |
81270-3 |
JAK2
(Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe
(V617F) variant |
1500 |
|
28 |
81270-4 |
JAK2
(Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe
(V617F) variant |
2363 |
|
29 |
81315 |
PML/RARalpha,
(t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg, promyelocytic
leukemia) translocation analysis; common breakpoints (eg, intron 3 and intron
6), qualitative or quantitative |
1156 |
|
30 |
81315-1 |
PML/RARalpha,
(t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg,
promyelocytic leukemia) translocation analysis; common breakpoints (eg,
intron 3 and intron 6), qualitative or quantitative |
605 |
|
31 |
81405 |
Molecular
pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence
analysis, mutation scanning or duplication/deletion variants of 11-25 exons)
CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide2) (eg, steroid
21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence
FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L),
full gene sequence MPZ (myelin protein zero) (eg, Charcot-Marie-Tooth), full
gene sequence NEFL (neurofilament, light polypeptide) (eg,
Charcot-Marie-Tooth), full gene sequence RET (ret proto-oncogene) (eg,
multiple endocrine neoplasia, type 2A and familial medullary thyroid
carcinoma), targeted sequence analysis (eg, exons 10, 11, 13-16) SDHB
(succinate dehydrogenase complex, subunit B, iron sulfur) (eg, hereditary
paraganglioma), full gene sequence TGFBR1 (transforming growth factor, beta
receptor 1) (eg, Marfan syndrome), full gene sequence TGFBR2 (transforming
growth factor, beta receptor 2) (eg, Marfan syndrome), full gene sequence
THRB (thyroid hormone receptor, beta) (eg, thyroid hormone resistance,
thyroid hormone beta receptor deficiency), full gene sequence or targeted
sequence analysis of >5 exons TP53 (tumor protein 53) (eg, Li-Fraumeni
syndrome, tumor samples), full gene sequence or targeted sequence analysis of
>5 exons VWF (von Willebrand factor) (eg, von Willebrand disease type 2N),
targeted sequence analysis (eg, exons 18-20, 23-25) |
1278 |
|
32 |
New |
Chimerism
testing |
2330 |
|
33 |
New |
Neopterin |
375 |
|
34 |
New |
AMPD1
Gene Mutations |
1430 |
|
35 |
New |
West-Nile-Virus
IgM spec. abs. (quant.) |
332 |
|
36 |
New |
West-Nile-Virus
IgG spec. abs. (qual.) |
332 |
|
37 |
New |
West-Nile-Virus
IgG spec. abs. (quant.) |
332 |
|
38 |
New |
Polycyctic
Liver Disease (PCLD)NGS. |
6830 |
|
39 |
2082735 |
JC
Virus PCR,CSF |
405 |
|
40 |
2082736 |
Copper
Urine,24 Hrs |
125 |
|
41 |
2082737 |
Citrate
Urine,24 Hrs |
161 |
|
42 |
2082738 |
HLA-DQ2/8(Celiac
Disease) |
530 |
|
43 |
2082739 |
BRAF
V600E Mutation |
1513 |
|
44 |
2082740 |
Slides
for second opinion |
250 |
|
45 |
2082741 |
Retina
Abs |
179 |
|
46 |
2082742 |
Cholestenol
Level |
73 |
|
47 |
2082743 |
Phospholipase
A2 Receptor Abs Qual |
247 |
|
48 |
2082744 |
Phospholipase
A2 Receptor Abs Quan |
247 |
|
49 |
2082745 |
Cimzia
Level & Abs |
2021 |
|
50 |
2082746 |
Neopterin,
Urine |
339 |
|
51 |
2082747 |
PEX16/PC
Gene |
5416 |
|
52 |
2082748 |
Inhibitor
Screening |
238 |
|
53 |
2082749 |
HEV
abs. (IgG/immunoblot) |
185 |
|
54 |
2082750 |
HEV
abs. (IgM/immunoblot) |
185 |
|
55 |
2082751 |
Myelin
Oligodendrocyte Glycoprotien Abs |
269 |
|
56 |
2082752 |
CA 125
Body Fluids |
185 |
|
57 |
2082753 |
Carnitine,Total
(Serum) |
206 |
|
58 |
2082754 |
Breast
& Ovarian Cancer 1 &2 |
4380 |
|
59 |
2082755 |
Zinc
Transporter 8 Abs |
233 |
|
60 |
2082758 |
Familial
Mutation Testing (one mutation, sequencing) |
980 |
|
61 |
2082759 |
17-OH
Pregnenolone, 24 Hrs Urine |
364 |
|
62 |
2082760 |
Mutational
Analysis CML(Chronic Myeloid Leukaemia) |
1509 |
|
63 |
2090001 |
Fatty
Acid Profile, Comprehensive (C8-C26) |
200 |
|
64 |
2090002 |
Glucopsychosine,
Blood Spot |
1820 |
|
65 |
2090003 |
Ceramide
Trihexosides and Sulfatides, Urine |
2366 |
|
66 |
2090004 |
Tartrate
Resistant Acid Phosphatase (TRAP) |
1915 |
|
67 |
2090005 |
Chitotriosidase |
427 |
|
68 |
2090006 |
M GLUR
5 Receptor Abs,Serum |
256 |
|
69 |
2090007 |
M GLUR
5 Receptor Abs,CSF |
176 |
|
70 |
2090008 |
SOX1
ABS,Serum |
206 |
|
71 |
2090009 |
SOX1
ABS,CSF |
126 |
|
72 |
2090010 |
GABA-B-Receptor
1 ABS,Serum |
184 |
|
73 |
2090011 |
GABA-B-Receptor
1 ABS,CSF |
104 |
|
74 |
2090012 |
Glycine
Receptor Abs.IgG,Serum |
256 |
|
75 |
2090013 |
Glycine
Receptor Abs.IgG,CSF |
176 |
|
76 |
2090014 |
Galactosemia
(GALT) gene |
3118 |
|
77 |
2090015 |
Oxalate
,Plasma |
182 |
|
78 |
2090016 |
Beta-Amyloid
42/40 Ratio, CSF |
8498 |
|
79 |
81402-1 |
Molecular
pathology procedure, Level 3 (eg, > 10 SNPs, 2-10 methylated variants, or
2-10 somatic variants [typically using non-sequencing target variant
analysis], immunoglobulin and T-cell receptor gene rearrangements,
duplication/deletion variants 1 exon) CYP21A2 (cytochrome P450, family 21,
subfamily A, polypeptide 2) (eg, congenital adrenal hyperplasia,
21-hydroxylase deficiency), common variants (eg, IVS2-13G, P30L, I172N, exon
6 mutation cluster [I235N, V236E, M238K], V281L, L307FfsX6, Q318X, R356W,
P453S, G110VfsX21, 30-kb deletion variant) ESR1/PGR (receptor 1/progesterone
receptor) ratio (eg, breast cancer) KIT (v-kit Hardy-Zuckerman 4 feline
sarcoma viral oncogene homolog) (eg, mastocytosis), common variants (eg,
D816V, D816Y, D816F) MEFV (Mediterranean fever) (eg, familial Mediterranean
fever), common variants (eg, E148Q, P369S, F479L, M680I, I692del, M694V,
M694I, K695R, V726A, A744S, R761H) MPL (myeloproliferative leukemia virus
oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder),
common variants (eg, W515A, W515K, W515L, W515R) TRD@ (T cell antigen
receptor, delta) (eg, leukemia and lymphoma), gene rearrangement analysis,
evaluation to detect abnormal clonal population |
980 |
|
80 |
81402-2 |
Molecular
pathology procedure, Level 3 (eg, > 10 SNPs, 2-10 methylated variants, or
2-10 somatic variants [typically using non-sequencing target variant
analysis], immunoglobulin and T-cell receptor gene rearrangements,
duplication/deletion variants 1 exon) CYP21A2 (cytochrome P450, family 21,
subfamily A, polypeptide 2) (eg, congenital adrenal hyperplasia,
21-hydroxylase deficiency), common variants (eg, IVS2-13G, P30L, I172N, exon
6 mutation cluster [I235N, V236E, M238K], V281L, L307FfsX6, Q318X, R356W, P453S,
G110VfsX21, 30-kb deletion variant) ESR1/PGR (receptor 1/progesterone
receptor) ratio (eg, breast cancer) KIT (v-kit Hardy-Zuckerman 4 feline
sarcoma viral oncogene homolog) (eg, mastocytosis), common variants (eg,
D816V, D816Y, D816F) MEFV (Mediterranean fever) (eg, familial Mediterranean
fever), common variants (eg, E148Q, P369S, F479L, M680I, I692del, M694V,
M694I, K695R, V726A, A744S, R761H) MPL (myeloproliferative leukemia virus
oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder),
common variants (eg, W515A, W515K, W515L, W515R) TRD@ (T cell antigen
receptor, delta) (eg, leukemia and lymphoma), gene rearrangement analysis,
evaluation to detect abnormal clonal population |
1928 |
|
81 |
81403 |
Molecular
pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence
analysis, analysis of > 10 amplicons using multiplex PCR in 2 or more
independent reactions, mutation scanning or duplication/deletion variants of
2-5 exons) ABL1 (c-abl oncogene 1, receptor tyrosine kinase) (eg, acquired
imatinib tyrosine kinase inhibitor resistance), variants in the kinase domain
DAZ/SRY (deleted in azoospermia and sex determining region Y) (eg, male
infertility), common deletions (eg, AZFa, AZFb, AZFc, AZFd) GJB1 (gap
junction protein, beta 1) (eg, Charcot-Marie-Tooth X-linked), full gene
sequence JAK2 (Janus kinase 2) (eg, myeloproliferative disorder), exon 12
sequence and exon 13 sequence, if performed KRAS (v-Ki-ras2 Kirsten rat
sarcoma viral oncogene) (eg, carcinoma), gene analysis, variant(s) in exon 2
MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor,
TPOR) (eg, myeloproliferative disorder), exon 10 sequence VHL (von
Hippel-Lindau tumor suppressor) (eg, von Hippel-Lindau familial cancer
syndrome), deletion/duplication analysis VWF (von Willebrand factor) (eg, von
Willebrand disease types 2A, 2B, 2M), targeted sequence analysis (eg, exon
28) |
980 |
|
82 |
84999-1 |
Unlisted
chemistry procedure |
1000 |
|
83 |
84999-2 |
Unlisted
chemistry procedure |
1293 |
|
84 |
84999-3 |
Unlisted
chemistry procedure |
9000 |
|
85 |
84999-4 |
Unlisted
chemistry procedure |
12500 |
|
86 |
86160-1 |
Complement;
antigen, each component |
120 |
|
87 |
86160-2 |
Complement;
antigen, each component |
210 |
|
88 |
86162-1 |
Complement;
total hemolytic (CH50) |
184 |
|
89 |
86162-2 |
Complement;
total hemolytic (CH50) |
268 |
|
90 |
82657-1 |
Enzyme
activity in blood cells, cultured cells, or tissue, not elsewhere specified;
nonradioactive substrate, each specimen |
600 |
|
91 |
82657-2 |
Enzyme
activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive
substrate, each specimen |
934 |
|
92 |
87797-1 |
Infectious
agent detection by nucleic acid (DNA or RNA), not otherwise specified; direct
probe technique, each organism |
214 |
|
93 |
87797-2 |
Infectious
agent detection by nucleic acid (DNA or RNA), not otherwise specified; direct
probe technique, each organism |
222 |